Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma von Alvarez-Benayas, Jaime, Trasanidis, Nikolaos, Katsarou, Alexia, Ponnusamy, Kanagaraju, Chaidos, Aristeidis, May, Philippa C., Xiao, Xiaolin, Bua, Marco, Atta, Maria, Roberts, Irene A. G., Auner, Holger W., Hatjiharissi, Evdoxia, Papaioannou, Maria, Caputo, Valentina S., Sudbery, Ian M., Karadimitris, Anastasios

Volltext

Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies von Cook, Lucy B., O’Dell, Gillian, Vourvou, Eleni, Palanicawandar, Renuka, Marks, Sasha, Milojkovic, Dragana, Apperley, Jane F., Loaiza, Sandra, Claudiani, Simone, Bua, Marco, Hockings, Catherine, Macdonald, Donald, Chaidos, Aris, Pavlu, Jiri, Cooper, Nichola, Fidler, Sarah, Randell, Paul, Innes, Andrew J.

Volltext

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia von Wadhwa, Jyoti, Szydlo, Richard M., Apperley, Jane F., Chase, Andrew, Bua, Marco, Marin, David, Olavarria, Eduardo, Kanfer, Edward, Goldman, John M.

Volltext

Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy von Ibrahim, Amr R, Milojkovic, Dragana, Bua, Marco, Khorshad, Jamshid S, Szydlo, Richard, Eliasson, Lina, Foroni, Letizia, Reid, Alistair, Lavallade, Hugues de, Rezvani, Katayoun, Goldman, John M., Apperley, Jane, Marin, David

Volltext

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies von Neelakantan, Pratap, Gerrard, Gareth, Lucas, Claire, Milojkovic, Dragana, May, Philippa, Wang, Lihui, Paliompeis, Christos, Bua, Marco, Reid, Alistair, Rezvani, Katayoun, O'Brien, Stephen, Clark, Richard, Goldman, John, Marin, David

Volltext

Optimal, Off-the-Shelf, CAR-iNKT Cell Platform-Based Immunotherapy for Multiple Myeloma von Ponnusamy, Kanagaraju, Randzavola, Lyra, Ren, Hongwei, Karaxhuku, Klesti, Lye, Bryan, Leonardos, Dimitrios, Nadafi, Reza, Sarkar, Irene, Leontari, Ilia, Sabrin, Farah, Zaidi, Mehmood, Bua, Marco, Atta, Maria, Katsarou, Alexia, Roberts, Irene, Chaidos, Aristeidis, Karadimitris, Anastasios

Volltext

Distinct Chromatin Accessibility Changes, Aberrant Transcription Factor Networks Combined with Novel Oncogenic Enhancers Characterise Myeloma-Initiating Genetic Events von Trasanidis, Nikolaos, Alvarez-Benayas, Jaime, Katsarou, Alexia, Chaidos, Aristeidis, May, Philippa C, Ponnusamy, Kanagaraju, Xiao, Xiaolin, Bua, Marco, Atta, Maria, Roberts, Irene, Auner, Holger W, Hatjiharissi, Evdoxia, Papaioannou, Maria, Caputo, Valentina S, Sudbery, Ian, Karadimitris, Anastasios

Volltext

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients von Milojkovic, Dragana, Apperley, Jane F., Gerrard, Gareth, Ibrahim, Amr R., Szydlo, Richard, Bua, Marco, Reid, Alistair, Rezvani, Katayoun, Foroni, Letizia, Goldman, John, Marin, David

Volltext

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune‐mediated pathogenesis von De Lavallade, Hugues, Punnialingam, Sinthiya, Milojkovic, Dragana, Bua, Marco, Khorashad, Jamshid S., Gabriel, Ian H., Chaidos, Aristeidis, Olavarria, Eduardo, Goldman, John M., Apperley, Jane F., Marin, David

Volltext

Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response von Kuwabara, Aya, Babb, Anna, Ibrahim, Amr, Milojkovic, Dragana, Apperley, Jane, Bua, Marco, Reid, Alistair, Foroni, Letizia, Rezvani, Katayoun, Goldman, John, Marin, David

Volltext

Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects von Neelakantan, Pratap, Rezvani, Katayoun, May, Philippa, Gerrard, Gareth, Marco, Bua, Paliompeis, Christos, Reid, Alistair, Goldman, John, Marin, David, Milojkovic, Dragana

Volltext

Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors von Tornatore, Laura, Sandomenico, Annamaria, Raimondo, Domenico, Low, Caroline, Rocci, Alberto, Tralau-Stewart, Cathy, Capece, Daria, D’Andrea, Daniel, Bua, Marco, Boyle, Eileen, van Duin, Mark, Zoppoli, Pietro, Jaxa-Chamiec, Albert, Thotakura, Anil K., Dyson, Julian, Walker, Brian A., Leonardi, Antonio, Chambery, Angela, Driessen, Christoph, Sonneveld, Pieter, Morgan, Gareth, Palumbo, Antonio, Tramontano, Anna, Rahemtulla, Amin, Ruvo, Menotti, Franzoso, Guido

Volltext

Tandem Autologous Stem Cell Transplantation in Chemorefractory Multiple Myeloma von Garnett, Catherine, Giles, Chrissy, Ahmed, Osman, Lasa, Maialen, Auner, Holger W., MacDonald, Donald, Marks, Sasha, Marin, David, Milojkovic, Dragana, Pavlu, Jiri, Bua, Marco, Abdalla, Saad, Kanfer, Edward J, Apperley, Jane, Rahemtulla, Amin

Volltext

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib von Milojkovic, Dragana, Ibrahim, Amr R, Foroni, Letizia, Lucas, Claire, Gerrard, Gareth, Wang, Lihui, Szydlo, Richard M, Clark, Richard E, Apperley, Jane F, Bua, Marco, Pavlu, Jiri, Paliompeis, Christos, Reid, Alistair, Rezvani, Katy, Goldman, John M, Marin, David

Volltext

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib von Gabriel, Ian H, Marin, David, Ahmad, Shahzad, Foroni, Letizia, de Lavallade, Hugues, Clark, Richard E., O'Brien, Stephen, Sergeant, Ruhena, Milojkovic, Dragana, Bua, Marco, Alsuliman, Abdullah, Khoder, Ahmad, Stringaris, Kate, Cooper, Nichola, Goldman, John M., Apperley, Jane F., Rezvani, Katayoun

Volltext

Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs von Ibrahim, Amr R, Bua, Marco, Khorshad, Jamshid S, Milojkovic, Dragana, Eliasson, Lina, Szydlo, Richard, Foroni, Letizia, Reid, Alistair, de Lavallade, Hugues, Rezvani, Katayoun, Goldman, John M., Apperley, Jane, Marin, David

Volltext

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Mem... von de Lavallade, Hugues, Marin, David, Hart, Melanie, Sekine, Takuya, Gabriel, Ian, Alsuliman, Abdullah, Bazeos, Alexandra, Khoder, Ahmad, Stringaris, Kate, Khorashad, Jamshid, Cooper, Nichola, Milojkovic, Dragana, Foroni, Letizia, Szydlo, Richard M, Chaidos, Aristeidis, Ibrahim, Amr R, Bua, Marco, Goldman, John M, Apperley, Jane F, Kelleher, William P, Rezvani, Katayoun

Volltext

Second Autologous Stem Cell Transplantation Is Effective Salvage Therapy for Relapsed Multiple Myeloma von Chaidos, Aristeidis, Giles, Chrissy, Auner, Holger W, Bua, Marco, Pavlu, Jiri, Smith, Ellena, Kanfer, Edward, MacDonald, Donald, Apperley, Jane F., Rahemtulla, Amin

Volltext

T-Cell and B-Cell Responses After Vaccination against Influenza Virus and Pneumococcus in Chronic Phase CML Patients Treated with Tyrosine Kinase Inhibitors von de Lavallade, Hugues, Hart, Melanie, Gabriel, Ian H, Kelleher, Peter, Alsuliman, Abdullah, Khoder, Ahmad, Milojkovic, Dragana, Foroni, Letizia, Bua, Marco, Apperley, Jane F., Goldman, John M, Marin, David, Rezvani, Katayoun

Volltext

Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa von Marin, David, Marktel, Sarah, Szydlo, Richard, Klein, John P, Bua, Marco, Foot, Nicola, Olavarria, Eduardo, Shepherd, Pat, Kanfer, Edward, Goldman, John M, Apperley, Jane F

Volltext